ACHV READ THE FULL ACHV RESEARCH REPORT Update for 2025 Achieve Life Sciences, Inc. (NASDAQ:ACHV) has been busy since its ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

We are delighted to welcome Kristen and Nancy to our Board of Directors,” said Tom King, Executive Chairman of Achieve’s Board of Directors. “Their wealth of knowledge and experience in strategic ...

(Bloomberg) -- GSK Plc is in talks to buy biotech company IDRx, people with knowledge of the matter said, a deal that would see the British drugmaker further boost its growing oncology portfolio. The ...

She is the co-founder of PowerZone Trading, a company that has provided programming, consulting, and strategy development services to active traders and investors since 2004. Diane Costagliola is ...

GSK hosted the third annual RespiVerse Meeting on December 13 and 14 in Bangkok, Thailand. The event brought together renowned international speakers and healthcare professionals from 17 countries to ...

Those developments have placed much more onus on other projects – and particularly GSK's RSV vaccine – to deliver quickly. Earlier this month, the company reported top-line efficacy data from ...

Key stocks in focus include General Insurance Corp, ONGC, SpiceJet, GSK Pharma, and Cipla due to various developments. Notable updates include the government's stake sale in General Insurance Corp and ...

Finally, Berenberg Bank decreased their price target on shares of GSK from GBX 1,820 ($22.83) to GBX 1,600 ($20.07) and set a “buy” rating for the company in a report on Friday, November 29th.

Jemperli is central to the company’s immuno-oncology research and development efforts. AnaptysBio discovered Jemperli, which was licensed to TESARO, as part of a partnership and exclusive licence ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...